Yazar "Unlu, Ozan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Acute onset seronegative autoimmune hepatitis: are simplified diagnostic criteria sufficient?
    (LIPPINCOTT WILLIAMS & WILKINS, 2016) Yilmaz, Bulent; Unlu, Ozan; Evcen, Recep; Ugurluoglu, Ceyhan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Endoluminal Bariatric Interventions : Where do we stand ? Where are we going ?
    (UNIV CATHOLIQUE LOUVAIN-UCL, 2015) Unlu, Ozan; Okoh, Alexis; Yilmaz, Bulent; Roach, Emir C.; Olayan, May; Shatnawei, Abdullah
    Background : Obesity is an epidemic leading to high morbidity, mortality, and therefore health-related costs. Thus, there is a huge need for development of safe and effective treatments. Even though success rates of conservative methods are highly limited, the surgical approaches lead to major complications in as many as 25% of the patients. In this study, we aimed to review the currently available, less-invasive, endoscopic bariatric techniques which provides an option to reduce the risks of the patients and the medical costs. Methods : A systematic literature review through Pubmed and Medline was performed to find the studies on this topic, and all controlled clinical trials, case reports, and case series were reviewed. Results : Endoluminal bariatric interventions include restrictive, malabsorptive approaches, and other techniques including transpyloric shuttle, botulinum toxin, gastric pacing and vagal nerve stimulation. Restrictive procedures act by limiting the gastric volume and leading to early satiety, while malabsorptive procedures create a malabsorption state. Transpyloric shuttle is a device decreasing the rate of gastric emptying. Botox injection causes a delay in gastric emptying, and vagal nerve stimulation modulates eating behavior. Conclusion : Endoluminal bariatric techniques can become the primary choice of therapy in the near future for bariatric care.
  • Küçük Resim Yok
    Öğe
    Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients
    (UNIV CATHOLIQUE LOUVAIN-UCL, 2016) Yilmaz, Bulent; Can, Guray; Ucmak, Feyzullah; Arslan, Ali Osman; Solmaz, Ihsan; Unlu, Ozan; Duzenli, Selma
    Aim : Few data are available regarding the effects of interleukin 28B (IL28B) polymorphisms in chronic hepatitis D (CHD) patients. This study investigated the relationship between IL28B polymorphisms and the response of patients with CHD infections to pegylated interferon (PEG-IFN) therapy. Materials and methods : A total of 101 CHD patients were selected, 80 of whom (46 males; median age 41 years) satisfied the inclusion criteria and were enrolled in the study. Thirty-seven patients were treated with peg-IFNa for at least 12 months and were followed for a median of 18 months (range, 12-30 months). The primary treatment endpoint was the suppression of HDV replication, as documented by the loss of detectable HDV RNA in serum. Geno-typing was used to analyse the IL28B polymorphisms rs12979860 and rs8099917 according to the virological response. Results : After treatment, a sustained viral response (SVR) was achieved in 19 (51%) of the patients treated with PEG-INF. The IL28B genotypes in the 80 patients were as follows : CC in 36 (45%), CT in 33 (41%) and TT in 11 (14%) for rs12979860, and GG in 4 (5%), GT in 27 (34%) and TT in 49 (61%) for rs8099917. SVR was achieved in 5 (26%), 10 (53%) and 4 (21%) patients with CC, CT and TT at rs12979860, respectively, and one (5%), nine (47%) and nine (47%) patients with GG, GT and TT at rs8099917, respectively. There were differences in the SVR among genotypes (rs12979860 and rs8099917; chi-squared test, p = 0.047). Conclusion : IL28B predicts the PEG-IFN response in patients with CHD infection.